Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787028 | 1.00 | NPC1 (0.51) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL20338921 | 0.88 | ANO1 (0.58) | ALDH1A1POLBTP53MAPTMEN1 | |
| SCHEMBL29786962 | 0.88 | ANO1 (0.58) | ALDH1A1POLBTP53MAPTMEN1 | |
| SCHEMBL20338675 | 0.85 | ANO1 (0.48) | ALDH1A1POLBCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29786981 | 0.85 | ANO1 (0.48) | ALDH1A1POLBCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20338681 | 0.84 | MEN1 (0.56) | NPC1RAB9AALDH1A1POLBLMNA | |
| SCHEMBL22726251 | 0.84 | JAK2 (0.50) | ALDH1A1POLBTP53CYP1A2CYP2C19 | |
| SCHEMBL29786917 | 0.84 | L3MBTL1 (0.56) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL20338685 | 0.84 | L3MBTL1 (0.56) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL20338809 | 0.84 | CSNK2A1 (0.55) | NPC1RAB9AALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | MINORYX THERAPEUTICS S.L. (ES) | 2022-09-13 | — | — | US | claimed |
| CN-110494432-B | Isoquinoline compounds, methods of preparation thereof and therapeutic use thereof in disorders associated with altered beta-galactosidase activity | 米尼奥尔克斯治疗有限公司 | 2022-08-12 | — | — | CN | claimed |
| EP-3562821-B9 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2021-05-26 | — | — | EP | claimed |
| EP-3562821-B1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2020-12-02 | — | — | EP | claimed |
| US-20200071294-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2020-03-05 | — | — | US | claimed |
| EP-3562821-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | Minoryx Therapeutics S.L. (ES) | 2019-11-06 | — | — | EP | claimed |
| WO-2018122746-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2018-07-05 | — | — | WO | claimed |
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | MINORYX THERAPEUTICS S.L. (ES) | 2022-09-13 | — | — | US | disclosed |
| CN-110494432-B | Isoquinoline compounds, methods of preparation thereof and therapeutic use thereof in disorders associated with altered beta-galactosidase activity | 米尼奥尔克斯治疗有限公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-3562821-B9 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2021-05-26 | — | — | EP | disclosed |
| EP-3562821-B9 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2021-05-26 | — | — | EP | disclosed |
| EP-3562821-B1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2020-12-02 | — | — | EP | disclosed |
| EP-3562821-B1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2020-12-02 | — | — | EP | disclosed |
| US-20200071294-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2020-03-05 | — | — | US | disclosed |
| US-20200071294-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2020-03-05 | — | — | US | disclosed |
| EP-3562821-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | Minoryx Therapeutics S.L. (ES) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122746-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018122746-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | GLB1, GBA1, GALC | NPC1 378/4885RAB9A 755/4885ALDH1A1 205/4885 |
| US-20200071294-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | GLB1, GBA1, GALC | NPC1 378/4885RAB9A 755/4885ALDH1A1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.